IRIS
CHIMENTI, SERGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 49.671
AS - Asia 6.547
EU - Europa 5.900
SA - Sud America 850
Continente sconosciuto - Info sul continente non disponibili 818
AF - Africa 160
OC - Oceania 54
Totale 64.000
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 49.331
SG - Singapore 2.660
CN - Cina 1.633
DE - Germania 840
IT - Italia 789
UA - Ucraina 780
RU - Federazione Russa 717
BR - Brasile 701
HK - Hong Kong 530
FR - Francia 482
IE - Irlanda 479
VN - Vietnam 478
SE - Svezia 457
GB - Regno Unito 429
FI - Finlandia 272
CA - Canada 217
BD - Bangladesh 203
PL - Polonia 196
KR - Corea 185
IN - India 162
JP - Giappone 155
TR - Turchia 81
NL - Olanda 78
ES - Italia 71
PK - Pakistan 64
ID - Indonesia 60
AR - Argentina 52
BE - Belgio 52
AU - Australia 48
EG - Egitto 44
MX - Messico 44
CH - Svizzera 42
ZA - Sudafrica 35
IQ - Iraq 32
PH - Filippine 31
RO - Romania 30
IR - Iran 29
TW - Taiwan 29
UZ - Uzbekistan 28
MY - Malesia 27
CO - Colombia 26
AT - Austria 23
EC - Ecuador 23
KG - Kirghizistan 23
JM - Giamaica 22
GR - Grecia 20
EU - Europa 19
IL - Israele 19
TH - Thailandia 19
AE - Emirati Arabi Uniti 18
HU - Ungheria 17
LT - Lituania 17
CZ - Repubblica Ceca 16
MA - Marocco 16
PT - Portogallo 16
SK - Slovacchia (Repubblica Slovacca) 16
CL - Cile 15
CR - Costa Rica 14
NG - Nigeria 14
DK - Danimarca 13
EE - Estonia 11
OM - Oman 11
SA - Arabia Saudita 11
KZ - Kazakistan 10
NP - Nepal 10
VE - Venezuela 10
DZ - Algeria 9
JO - Giordania 9
PY - Paraguay 9
RS - Serbia 9
TN - Tunisia 9
HR - Croazia 8
NI - Nicaragua 8
PE - Perù 8
ET - Etiopia 7
TT - Trinidad e Tobago 7
LB - Libano 6
LV - Lettonia 6
CY - Cipro 5
GT - Guatemala 5
HN - Honduras 5
KE - Kenya 5
NO - Norvegia 5
NZ - Nuova Zelanda 5
AZ - Azerbaigian 4
BJ - Benin 4
DO - Repubblica Dominicana 4
PR - Porto Rico 4
SN - Senegal 4
BH - Bahrain 3
BO - Bolivia 3
GH - Ghana 3
KW - Kuwait 3
MD - Moldavia 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BS - Bahamas 2
GA - Gabon 2
Totale 63.175
Salva come PNG Salva come JPEG
Città #
Woodbridge 13.772
Wilmington 10.832
Houston 9.455
Fairfield 1.589
Singapore 1.324
Ann Arbor 1.272
Ashburn 1.261
Chandler 1.064
San Jose 772
Jacksonville 689
Seattle 675
Beijing 568
Cambridge 562
Hong Kong 495
Dublin 476
Medford 386
New York 333
Council Bluffs 298
Dearborn 290
Zhengzhou 264
Santa Clara 241
The Dalles 241
Los Angeles 196
Lawrence 181
Dallas 154
Rome 151
Kraków 137
Hanoi 134
Tokyo 125
Ho Chi Minh City 121
Buffalo 103
Helsinki 103
Moscow 102
San Diego 98
Lauterbourg 89
Mülheim 87
Shanghai 87
Menlo Park 85
Munich 83
Denver 78
Boardman 77
São Paulo 77
Redwood City 62
Milan 60
Chicago 55
London 53
Phoenix 50
Toronto 49
Montreal 44
Brooklyn 42
Redondo Beach 42
Stockholm 41
Atlanta 40
Warsaw 40
Hefei 39
Nanjing 39
San Mateo 39
Guangzhou 38
Orem 38
Bar Harbor 36
Norwalk 33
Brussels 29
Jakarta 29
Naples 29
Frankfurt am Main 28
Jönköping 28
University Park 28
Ankara 27
Turin 27
Verona 27
Columbus 26
Detroit 24
Falls Church 24
Madrid 24
Nuremberg 24
San Francisco 24
Hangzhou 22
Philadelphia 22
Boston 21
Chennai 21
Kunming 21
Da Nang 20
Haiphong 20
Manchester 20
Mountain View 20
Palo Alto 20
Nanchang 19
Belo Horizonte 18
Dong Ket 18
Auburn Hills 17
Johannesburg 17
Lahore 17
Poplar 17
Queens 17
Curitiba 16
Kingston 16
Florence 15
Paris 15
Rio de Janeiro 15
Amsterdam 14
Totale 50.803
Salva come PNG Salva come JPEG
Nome #
European S3-guidelines on the systemic treatment of psoriasis vulgaris 1.681
Long-term use of a new topical formulation containing piroxicam 0.8% and sunscreen: efficacy and tolerability on actinic keratosis. A proof of concept study 1.248
Quality of life in patients with plaque psoriasis treated with biologic therapies 829
Atopic dermatitis and dental manifestations 558
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis 554
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa 551
Topical lactoferrin can improve stable psoriatic plaque 520
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis 518
Alopecia areata e trachionichia associato a sindrome da insufficienza endocrina plurighiandolare. 518
Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia 514
Clinical aspects of the oral cavity in patients with psoriasis: an initial study and a proposal of a new evaluation method 514
Inflammatory linear verrucous epidermal nevus and epilepsy: remission during valproic acid therapy 509
Superficial and nodular basal cell carcinomas treated with an immune response modifier: a report of seven patients 506
Effects of TNF-α and IL-1 β on the activation of genes related to inflammatory, immune responses and cell death in immortalized human HaCat keratinocytes 505
IL-21 Promotes Skin Recruitment of CD4+ Cells and Drives IFN- -Dependent Epidermal Hyperplasia 504
-174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers 502
Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis 499
Exclusion of CARD15/NOD2 as a candidate susceptibility gene to psoriasis in the Italian population 495
Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study 495
Successful treatment of multiple filiform facial warts with imiquimod 5% cream in a patient infected by human immunodeficiency virus 492
Apremilast for the treatment of psoriasis. 492
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 490
Tazarotene as alternative topical treatment for onychomycosis 482
Combination of low-dosage cyclosporine and topical pimecrolimus in severe atopic dermatitis with chronic hepatitis B [10] 480
Tazarotene 0-1% gel for psoriasis of the fingernails and toenails: an open, prospective study [9] 476
Golimumab in Patients Affected by Moderate to Severe Psoriatic Arthritis: An Open-Label Study in Thirty-Two Patients Previously Treated with Other Biologics 472
Actinic keratosis treated with an immune response modifier: a case report of six patients 471
Psoriasis, kaposi's sarcoma and hodgkin's disease in a patient with down's syndrome [2] 468
New topical treatments for psoriasis 467
Increased levels of IL-17 in tear fluid of moderate-to-severe psoriatic patients is reduced by adalimumab therapy 467
Treatment of trachyonychia with tazarotene 464
Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis 463
Stress reactivity in psoriatic patients 462
Alopecia areata e trachionichia associato a sindrome da insufficienza indocrina plurighiandolare 455
Experimental T cells immunotherapy by tumor-loaded ECP-generated dendritic antigen presenting cells 455
Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases 454
Lung nodule and facial erythematous plaques: a quiz 452
Trimethoprim-sulfamethoxazole induced erythrodermic psoriasis 451
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 451
Psoriasis, from pathogenesis to therapeutic strategies: IL-21 as a novel potential therapeutic target 450
Diagnosis of pigmented skin lesions by dermoscopy: web-based training improves diagnostic performance of non-experts 449
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 447
Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population 446
Phrynoderma: a cutaneous sign of an inadequate diet 446
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study 445
Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment 445
The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice 444
Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports 444
The significance of the development of antinuclear antibodies during infliximab treatment 442
Reply to Scalone and Cortesi: ‘‘Cost-Utility Analysis of Biologic Therapies to Treat Chronic Plaque Psoriasis in Italy: The Importance of Using Updated and Adequate Social Tariffs to Calculate QALYs’’ 440
High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: Efficacy, safety and impact on patients' quality of life 439
Melanoma-associated markers expression in blood: MUC-18 is associated with advanced stages in melanoma patients 438
PSORS2 markers are not associated with psoriatic arthritis in the Italian population 438
Cerebriform plantar hyperplasia: the clinico-pathological hallmark of Proteus syndrome 438
Infliximab therapy induces increased polyclonality of CD4+CD25+ regulatory T cells in psoriasis. 437
Treatment of lentigo maligna with tazarotene 0.1% gel 437
Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody 436
Characterization of the loricrin (LOR) gene as a positional candidate for the PSORS4 psoriasis susceptibility locus 436
Chronic mucocutaneous candidiasis and alopecia areata as cutaneous expressions of autoimmune polyglandular syndrome type I 435
Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. 434
Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study 433
Local treatment of chronic cutaneous leg ulcers with recombinant human granulocyte-macrophage colony-stimulating factor. 431
Remission and time of resolution of nail psoriasis during infliximab therapy [27] 430
Co-localization of susceptibility loci for psoriasis (PSORS4) and atopic dermatitis (ATOD2) on human chromosome 1q21 429
Topical use of calcitriol 3 microg/g ointment in the treatment of mild-to-moderate psoriasis: results from an open-label study 429
Severe acne successfully treated with etanercept 428
Usefulness of QuantiFERON®-TB Gold test in psoriatic patients under treatment with tumour necrosis factor blockers 427
Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face 426
Bullous dermatomyositis: A marker of poor prognosis and aggressive internal malignancy? 425
Oral lichen planus: Novel acquisitions in the pathogenesis and treatment 423
Bowenoid papulosis and invasive Bowen's disease: a multidisciplinary approach 421
The tumor suppressor activity of IKK alpha in stratified epithelia is exerted in part via the TGF-beta anti proliferative pathway 420
Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis 418
Localized morphea treated with imiquimod 5% and dermoscopic assessment of effectiveness 416
A 2-year history of an asymptomatic scalp nodule - Cutaneous metastasis from renal cell carcinoma. 415
Prevention of Dermatologic Side Effects of Bimatoprost 0.03% Topical Therapy 414
TNF-α antagonists and nail psoriasis: An open, 24-week, prospective cohort study in adult patients with psoriasis 414
Erysipeloid cutaneous metastasis from bladder carcinoma 411
Chronically Sun-damaged Melanomas Express Low Levels of Nuclear Glutathione-S-transferase-π: An Epidemiological and Clinicopathological Study in Italy 410
Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk 409
Tofacitinib for the treatment of psoriasis 408
Analysis of risk factors in cutaneous malignant melanoma: an italian population-based study 407
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 407
Influence and variation of the body mass index in patients treated with etancercept for psoriasis 402
Cyclosporine: a novel therapeutic approach for Burning Mouth Syndrome 402
Pyoderma vegetans and ulcerative colitis 398
The first skin cancer screening day at the Italian parliament: A Euromelanoma initiative 396
Cerebral cavernomas in a family with multiple cutaneous and uterine leiomyomas associated with a new mutation in the fumarate hydratase gene J Invest Dermatol. 2007 Sep;127(9):2271-3. 394
Disseminated pagetoid reticulosis presenting as cytotoxic CD4/CD8 double negative cutaneous T-cell lymphoma 392
Zosteriform metastasis of occult bronchogenic carcinoma 392
HIV-associated primary cutaneous anaplastic large cell lymphoma: A clinicopathological subset with more aggressive behavior? Case report and review of the literature 392
Severe erytrodermic psoriasis in child twins: From clinical-pathological diagnosis to treatment of choice through genetic analyses: Two case reports 390
Immunologic biomarkers for clinical and therapeutic management of psoriasis 388
Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene 387
Efficacy and safety of long-term infliximab therapy in moderate to severe psoriasis and psoriatic arthritis 385
Ichthyosiform mycosis fungoides: A neoplastic acquired ichthyosis [5] 383
Graham Little-Piccardi-Lassueur syndrome: effective treatment with cyclosporin A 383
Dermatitis artefacta in sporadic sclerodermoid hepatitis C virus-associated porphyria cutanea tarda 381
Small molecules and antibodies for the treatment of psoriasis: A patent review (2010–2015) 381
Insight into genetics of atopic dermatitis: future approaches and directions 380
Totale 46.927
Salva come PNG Salva come JPEG
Categoria #
all - tutte 152.844
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 152.844
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.631 0 0 0 138 59 177 102 113 146 184 141 571
2022/20232.770 258 230 141 407 234 582 181 155 286 27 168 101
2023/20241.153 119 52 81 50 104 290 81 106 23 38 25 184
2024/20254.209 176 802 431 261 112 240 380 210 348 327 476 446
2025/20267.045 560 328 807 602 566 230 843 676 734 643 777 279
2026/20272.294 399 364 1.277 254 0 0 0 0 0 0 0 0
Totale 64.000